Get the latest Science News and Discoveries
Second Phase 3 clinical trial again shows dupilumab lessens disease in COPD patients with type 2 inflammation - EurekAlert
Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine. This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD.
None
Or read this on Eureka Alert